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ABSTRACT
Introduction Hyperbaric oxygen therapy (HBOT) has been 
suggested to improve healing of lower limb ulcers, though 
the quality of available evidence is weak to moderate. 
This study assessed the opinions and use of HBOT by 
specialists treating lower limb ulcers.
Research design and methods Accredited vascular 
surgeons and podiatrists in Australia and New Zealand 
were sent an online survey via their professional 
organizations. The survey asked about their use and 
opinions of HBOT in treating lower limb ischemic, 
neuropathic and venous ulcers. Data were summarized 
with descriptive statistics. Non- parametric tests were 
used to compare survey results obtained from vascular 
surgeons and podiatrists.
Results 61 vascular surgeons and 40 podiatrists 
completed the survey. Thirty- seven specialists used 
HBOT for treating lower limb ulcers, with the remainder 
indicating they did not feel there was a role for HBOT 
(n=25) or did not have access to HBOT (n=39). Less than 
8% of specialists indicated that HBOT frequently or always 
had a role in treating ischemic, neuropathic or venous 
ulcers. Compared with podiatrists, vascular surgeons were 
significantly less likely to indicate HBOT had a treatment 
role for any ulcer type (p<0.001, p=0.004, and p<0.001, 
respectively), though significantly more likely to indicate 
they currently used HBOT for treating lower limb ulcers 
(p<0.001). Most specialists (n=76) believed that a large 
clinical trial is needed to determine the efficacy of HBOT in 
treating lower limb ulcers.
Conclusions Vascular surgeons and podiatrists do not 
feel HBOT has a frequent role in treating lower limb ulcers, 
but do feel there needs to be a large clinical trial to test its 
value.
INTRODUCTION
Lower limb ulcers, which are usually caused 
by neuropathy, venous or arterial disease, are 
an important cause of reduced health- related 
quality of life, increased risk of amputation 
and high healthcare costs.1–4 Established 
treatments for lower limb ulcers include 
compression bandaging, off- loading of high 
foot pressures and venous or arterial surgery, 
depending on the etiology of the ulcer.5 Not 
infrequently, these treatments fail to heal 
the ulcer, requiring additional therapies 
to prevent poor outcomes, such as major 
amputation.2–4 6 7 Hyperbaric oxygen therapy 
(HBOT) is a potential treatment option for 
lower limb ulcers. It is believed to promote 
healing by facilitating tissue oxygenation, 
promoting angiogenesis, and stimulating an 
effective immune response to aid control 
of infection.8 9 There is, however, ongoing 
debate on the effectiveness and indications 
for HBOT in treating lower limb ulcers.10 11
A recent meta- analysis of nine randomized 
trials reported that HBOT improved the odds 
of healing lower limb ulcers in people with 
diabetes.12 There were however methodolog-
ical weaknesses identified in most of the trials, 
such as a lack of sample size calculations and 
absence of blinding outcome assessments to 
group allocation.12 There was also substantial 
Significance of this study
What is already known about this subject?
 ► Hyperbaric oxygen therapy (HBOT) is recommend-
ed for the treatment of non- healing lower limb 
ulcers, though the quality of evidence supporting 
this recommendation is low to moderate, and the 
opinion of specialists who use this therapy is poorly 
understood.
What are the new findings?
 ► Vascular surgeons and podiatrists in Australia and 
New Zealand indicated that they perceive HBOT as 
having an infrequent role in the management of non- 
healing venous, ischemic, and neuropathic ulcers.
How might these results change the focus of 
research or clinical practice?
 ► Well- designed clinical trials are needed to provide 
high- quality evidence to inform on the appropri-
ate use of HBOT for lower limb ulcer management 
among vascular surgeons and podiatrists.
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heterogeneity in the findings.12 There was an uncharac-
teristically strong benefit of HBOT in one of the included 
trials and when this trial was removed from analyses this 
substantially reduced the benefit of HBOT.12 13 The 
most recent randomized trial reported that HBOT did 
not improve ulcer healing or reduce amputations.14 
The provision of HBOT is expensive, time consuming, 
inconvenient for patients (especially those living in rural 
areas), and has reported complications,15 such as baro-
trauma,16 which must be considered when making deci-
sions about its use. Despite these contrasting findings, 
current international guidelines recommend the use of 
HBOT for non- healing lower limb ulcers,5 7 17 18 while 
acknowledging that the evidence of benefit is only weak 
to moderate.
The aim of this study was to obtain opinions from two 
types of specialists about their use and perceptions of 
the role of HBOT in treating lower limb ulcers. Vascular 
surgeons and podiatrists were the specialists selected for 
this study, since these are two of the main specialties that 
manage lower limb ulcers, and may refer patients for 
HBOT in their practice.
PARTICIPANTS AND METHODS
Study design and participant recruitment
This was a cross- sectional study in which an online survey 
run through SurveyMonkey was distributed to vascular 
surgeons and podiatrists in Australia and New Zealand 
between August 2019 and March 2020. In these two 
countries, HBOT is funded for treating non- healing 
lower limb ulcers at public hospitals. Multiple organiza-
tions expected to have vascular surgeons or podiatrists 
as members were approached via email and requested to 
distribute the survey link. The organizations contacted 
were the Australia and New Zealand Society for Vascular 
Surgery, Diabetic Foot Australia, the Australian Wound 
Management Association, the Australian Diabetes 
Society, the New Zealand Ministry of Health, the Podiatry 
Board of Australia and Podiatry New Zealand. The initial 
request was sent in August 2019, with reminder requests 
sent in December 2019 and February 2020.
Procedure and data items collected
Specialists were first presented with an information 
and consent screen which outlined the purpose of the 
survey, including the abstract from a recent meta- analysis 
examining the efficacy of HBOT for treating lower limb 
ulcers.12 After consenting to participate, specialists were 
asked where their practice was located and their specialty. 
They were then asked whether they currently used HBOT 
in the treatment of lower limb ulcers and presented with 
statements related to their perceived role of HBOT in 
the treatment of ischemic, neuropathic or venous ulcers, 
which they rated on 5- point ordinal scales (never, rarely, 
sometimes, frequently or always). The final questions 
in the survey related to their access to HBOT facilities, 
criteria for HBOT therapy and the perceived need for 
more evidence on HBOT effectiveness. The full survey is 
shown in online supplementary material. In pilot testing, 
the survey took less than 5 min to complete. There were 
no incentives offered for participation.
Data analysis
To be considered a complete survey, specialists must have 
completed a minimum of the first seven survey ques-
tions (online supplementary material). These questions 
covered their opinion on the treatment role of HBOT 
for the three ulcer types and whether or not they used 
HBOT for treating lower limb ulcers in their practice. A 
descriptive analysis was conducted to determine the char-
acteristics of the participants and sum their responses. 
The 5- point ordinal scale ratings (never, rarely, some-
times, frequently, always) in response to the statements 
on perceived HBOT role for each ulcer type were scored 
as 1–5 respectively. These data were presented as median 
(IQR) and the responses of vascular surgeons and podia-




A total of 102 survey responses were received from 61 
vascular surgeons and 41 podiatrists, with 101 responses 
from 61 vascular surgeons and 40 podiatrists considered 
complete. Most specialists were practicing in the states of 
Queensland (n=41), New South Wales (n=20) or Victoria 
(n=15). Between one and seven respondents were prac-
ticing in each of the other Australian states and territo-
ries and 12 specialists (eight vascular surgeons and four 
podiatrists) were practicing in New Zealand.
Current use of HBOT for lower limb ulcers
Thirty- seven (36.6%) specialists indicated they currently 
used HBOT for the treatment of lower limb ulcers. The 
other specialists indicated that they did not feel there was 
a role for HBOT (n=25; 24.8%), or that they did not have 
access to HBOT (n=39; 38.6%). Most of those without 
HBOT access indicated that the resource simply had not 
been established in their practice setting (n=23; 22.7%), 
was too expensive (n=6; 5.9%), or was not felt to be bene-
ficial to the hospital (n=4; 4.0%). Responses provided in 
open- text comment boxes included: ‘Only some patients 
were able to travel for regular treatment’ (Podiatrist), ‘Not 
enough evidence to suggest HBOT is effective’ (Podiatrist), 
‘None in my town. I do refer the occasional one but most patients 
not willing to travel’ (Vascular surgeon), and ‘Limited use for 
the cost’ (Vascular surgeon).
Responses to statements about the role of HBOT for treating 
different types of ulcers
Only 8 (7.9%), 6 (5.9%) and 2 (2.0%) of the specialists 
indicated that HBOT ‘frequently’ or ‘always’ had a role 
in the treatment of ischemic, neuropathic and venous 
lower limb ulcers, respectively (table 1). In compar-
ison, 43 (42.6%), 27 (26.7%) and 24 (23.8%) specialists 
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indicated HBOT ‘sometimes’ had a role in the treatment 
of ischemic, neuropathic and venous lower limb ulcers, 
respectively (table 1). The remainder responded that 
HBOT ‘rarely’ or ‘never’ had a role in treating these 
ulcers (table 1).
Comparison of responses between vascular surgeons and 
podiatrists
Vascular surgeons were significantly less likely than podi-
atrists to indicate that HBOT frequently or always had 
a role in the treatment of ischemic, neuropathic and 
venous lower limb ulcers (p<0.001 for ischemic lower 
limb ulcers, p=0.004 for neuropathic lower limb ulcers, 
and p<0.001 for venous lower limb ulcers) (table 2).
Criteria for HBOT use
More than half (31; 50.8%) of vascular surgeons 
compared with only six (15%) podiatrists indicated 
that they currently used HBOT for treating lower limb 
ulcers (p<0.001) (table 3). For specialists who used 
HBOT for treating lower limb ulcers (n=37; 36.6%), a 
lack of response to other therapies, such as revascular-
ization, wound debridement, dressing and pressure 
off- loading, was most frequently cited as a criterion for 
patient selection (table 3). Free- text responses included: 
‘After debridement or drainage of mid- foot sepsis without 
macrovascular arterial compromise’ (Vascular surgeon), 
‘Post- revascularisation’ (Podiatrist), ‘Ulcers sometimes defy 
conventional categorization, e.g. ulcers over the Achilles tendon 
that have local ischaemic even when blood supply to the foot is 
good. These do well with HBOT’ (Vascular surgeon). Trans-
cutaneous oxygen pressures (TcPO2) (n=33; 32.7%) and 
ineligibility for other therapies (n=15; 14.9%) were also 
commonly cited as criteria for HBOT. ‘I ask the HBOT unit 
to determine TcPO2 to determine chance of benefit’ (Vascular 
surgeon).
Need for further randomized clinical trials
The vast majority of respondents (n=76; 75%) indicated 
that a large trial was needed to test the efficacy of HBOT 
in treating lower limb ulcers. The remainder believed 
that no trial was needed either due to strong evidence 
for this therapy (n=4; 4.0%), strong evidence against this 
therapy (n=5; 5.0%), or a belief that HBOT will never 
be an appropriate therapy (n=3; 3.0%). There were 
no significant differences in these responses between 
vascular surgeons and podiatrists.
DISCUSSION
This study investigated the opinions of vascular surgeons 
and podiatrists on the use of HBOT for lower limb ulcers. 
One- third of specialists completing this survey indicated 
that they actively use HBOT for ischemic, neuropathic, 
or venous leg ulcers, with few indicating it had a strong 
role in treatment for any of these ulcer types. Vascular 
surgeons were more likely to have access to and use 
HBOT, whereas podiatrists felt that it had a stronger role 
in treatment. When choosing HBOT as a treatment for 
these ulcers, a lack of response to other therapies and 
low TcPO2 were considered key criteria. Most specialists 
indicated that a large clinical trial was needed to assess 
the efficacy of HBOT in treating these ulcers. Overall, 
this study indicates the lack of high- quality evidence 
which supports the use of HBOT in managing lower limb 
ulcers, as reflected by the low number of specialists indi-
cating that they use it frequently for ulcer management.
International guidelines5 7 17 18 20–23 refer to several 
recent reviews10 18 24 and notable randomized controlled 
trials14 25–28 on HBOT efficacy in ulcer management. A 
number of these systematic reviews including the most 
recent12 have found that HBOT increases the proportion 
Table 1 Responses to statements about the role of hyperbaric oxygen therapy in treating different types of lower limb ulcers 
(n=101)
Statement Never Rarely Sometimes Frequently Always Median (IQR)
HBOT has a treatment role in ischemic foot ulcers. 13 (13) 37 (37) 43 (43) 7 (7) 1 (1) 3 (2–4)
HBOT has a treatment role in neuropathic foot ulcers. 24 (24) 44 (44) 27 (27) 5 (5) 1 (1) 2 (1–3)
HBOT has a treatment role in venous leg ulcers. 29 (29) 46 (46) 24 (24) 1 (1) 1 (1) 2 (1–3)
Data were presented as n (%) and median (IQR).
HBOT, hyperbaric oxygen therapy.
Table 2 Comparison between vascular surgeons and 





5- point ordinal 
scale—median (IQR) P value
HBOT has a treatment 
role in ischemic foot 
ulcers.




HBOT has a treatment 
role in neuropathic foot 
ulcers.
Vascular surgeons: 2 
(1–3)
0.004
  Podiatrists: 3 (2–4)
HBOT has a treatment 
role in venous leg ulcers.




Data were presented as n (%) and median response (IQR).
Mann- Whitney U test was used to compare specialist 
opinions.
HBOT, hyperbaric oxygen therapy.
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of ulcers that completely heal and reduces the incidence 
of major and minor amputations. Thus, current guide-
lines recommend HBOT is considered for non- healing 
lower limb ulcers. It is noted, however, that prior clinical 
trials have had conflicting findings and methodological 
shortcomings, highlighting the need for further well- 
designed trials to provide reliable guidance, which was 
also indicated by specialists in the current survey. Most 
of the current guidelines recommend HBOT for ulcer 
healing either in conjunction with standard therapy,17 or 
only when standard therapy has failed to heal the ulcer 
in a reasonable amount of time,5 7 18 20 22 which in most 
trials is considered as after 4 weeks of therapy.12 Vascular 
surgeons and podiatrists in this study reported that these 
were the directions that they most frequently followed 
when using HBOT. They indicated that they also consid-
ered HBOT when patients were not eligible for standard 
therapy and also used TcPO2 to guide use of HBOT, 
which is not listed in current guidelines.5 7 17 18 20–23
The reasons behind the variation between vascular 
surgeon and podiatrist in the use of HBOT and opin-
ions about the value of HBOT in ulcer healing iden-
tified in this study are not certain. Vascular surgeons 
typically work in tertiary hospitals where HBOT facilities 
are usually located, making it likely they have greater 
access to refer patients for this therapy than podiatrists, 
who more frequently work in community clinics. This 
may explain why vascular surgeons more frequently 
indicated that they refer patients for HBOT than podia-
trists, despite their opinions of it having a less frequent 
place in therapy. The reasons for this difference in 
opinions on the treatment role of HBOT may be due 
to variations in professional guidelines, reflecting ulcer 
etiology commonly managed by these specialists. The 
current international guideline published for vascular 
surgeons states that there is ongoing controversy about 
the value of HBOT for treating lower limb ulcers.5 The 
guidelines state that there may be a role for the use 
of HBOT to accelerate ulcer healing in people with 
diabetes with non- healing neuropathic ulcers and low- 
grade ischemia.5 This is in comparison to multiple 
Australian guidelines used by podiatrists, which appear 
to be more supportive for the use of HBOT, stating it 
may be considered as part of a comprehensive wound 
management program.29 30
Table 3 Specialist use of and selection criteria for hyperbaric oxygen therapy
Question/statement Specialist responses n (%)
Do you currently use HBOT for 
treating lower limb ulcers?
Vascular surgeons (n=61)
  Yes 31 (31)
  No 30 (30)
Podiatrists (n=40)
  Yes 6 (6)
  No 34 (34)
If you use HBOT for lower limb 
ulcers, how do you select patients 
for treatment? (select all that apply)
Transcutaneous oxygen pressure 19 (51)
Not suited to other therapies 9 (24)
Lack of response to other therapies 22 (60)
I use HBOT for lower limb ulcers 
based on: (select all that apply)
TcPO2 level less than 20 mm Hg 8 (22)
TcPO2 level less than 40 mm Hg 12 (32)
TcPO2 level less than 50 mm Hg 4 (11)
Another TcPO2 level to that described above 3 (8.1)
Not healing after a period of other therapy for 4 weeks 6 (16)
Not healing after a period of other therapy for 8 weeks 9 (24)
Not healing after a period of other therapy for 12 weeks 13 (35)
Not healing after a period of other therapy for 6 months 9 (24)
Not healing after a period of other therapy for >6 months 10 (27)
Lack of response to wound debridement 13 (35)
Lack of response to negative pressure wound therapy 14 (38)
Lack of response to regular wound dressings 18 (49)
Lack of response to pressure off- loading 16 (43)
Lack of response to revascularization 30 (81)
Oxygen challenge test with increased TcPO2 to >100 mm Hg in the 
chamber
11 (30)
HBOT, hyperbaric oxygen therapy; TcPO2, transcutaneous oxygen pressure.
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As a result of the aforementioned shortcomings in 
previous research, there is widespread consensus on 
the need for further research investigating the benefit 
(if any) of HBOT in ulcer healing,21 23 which was indi-
cated by the majority of vascular surgeons and podia-
trists in this study. This further research in the form of 
a well- powered randomized controlled trial would need 
to demonstrate a clear benefit of HBOT in ulcer wound 
healing through a methodologically sound approach 
that avoids shortcomings demonstrated in previous 
research. The outcomes of such a trial would inform 
guideline recommendations to direct a range of rele-
vant health professionals, including vascular surgeons 
and podiatrists, on the appropriateness and efficacy of 
HBOT in lower limb ulcer management.
The current study has a number of limitations that 
should be acknowledged. As the surveys were sent out 
to practitioners via professional societies, it was not 
possible to calculate the response rate. It is therefore 
unclear how representative the opinions obtained 
were of the overall community of vascular surgeons 
and podiatrists in Australia and New Zealand. Also, 
only two types of specialists who may refer patients for 
HBOT were included in this survey. Their opinions may 
differ from other relevant specialists, such as general 
practitioners, nurses and hyperbaric oxygen specialists. 
Lastly, only specialists from two countries were included 
in this survey. Their opinions may differ from special-
ists in other countries.
In conclusion, this survey suggests that approximately 
one- third of Australia and New Zealand vascular surgeons 
and podiatrists use HBOT in treating lower limb ulcers. 
These specialists mostly felt that HBOT only sometimes 
had a role in treating ischemic, neuropathic, or venous 
lower limb ulcers. A majority of specialists indicated that 
further high- quality research was needed to guide the use 
of this therapy and determine its effectiveness for ulcer 
management.
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